YOLFTbeta
Marinomed Biotech AG

Marinomed Biotech AG

MARI · VI · Healthcare / Biotechnology

4.00EUR-0.50 (-11.11%)

Price History

Full chart

Market Stats

Previous Close4.50
Open4.00
Day Range4.00 – 4.00
52-Week Range2.20 – 21.00
Volume0
Market Cap8.00M
P/E (TTM)0.41
Forward P/E4.03
EPS9.76
Dividend Yield0.00%
Beta-0.25
50-Day Avg4.62
200-Day Avg11.55

About

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Andreas Grassauer Ph.D.
  • Employees32
  • HeadquartersHovengasse 25, Korneuburg, Austria, 2100, Austria
  • Websitehttps://www.marinomed.com

Leadership

  • Mr. Andreas Grassauer Ph.D.Co-Founder, Chairman of Management Board & CEO · b. 1969
  • Ms. Eva Prieschl-Grassauer Ph.D.Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer · b. 1968
  • Ms. Gabriele RamAuthorized Signatory, Head of Finance & Member of Management Board
  • Ms. Stephanie KniepHead of Investor Relations

Financials

Income Statement

Currency: EUR2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.65M2.61M4.81M4.67M6.14M8.12M11.63M11.28M9.06M4.75M7.69M
Growth (%)--1.43%+84.45%-3.01%+31.68%+32.22%+43.12%-3.03%-19.67%-47.60%+62.02%
Cost of Revenue1.34M2.43M4.16M4.83M6.66M8.77M10.20M9.14M8.08M3.77M1.42M
Gross Profit1.31M176.16K651.42K-165.45K-512.30K-641.70K1.42M2.14M981.18K979.99K6.27M
Gross Margin49.37%6.75%13.54%-3.55%-8.34%-7.90%12.25%18.98%10.83%20.64%81.52%
Operating Expense2.56M1.72M2.33M5.00M5.78M5.22M5.57M7.01M5.98M7.93M6.51M
Operating Income-1.25M-1.55M-1.67M-5.16M-6.29M-5.86M-4.14M-4.87M-5.00M-6.95M-244.80K
Operating Margin-47.26%-59.35%-34.82%-110.62%-102.37%-72.15%-35.64%-43.21%-55.19%-146.49%-3.18%
EBITDA---1.22M-8.87M-6.22M-4.86M-3.58M-3.21M-4.53M-7.18M18.98M
EBITDA Margin---25.36%-189.99%-101.22%-59.88%-30.76%-28.49%-49.97%-151.27%246.77%
Net Income-1.41M-1.97M-2.38M-12.10M-7.22M-6.01M-5.89M-6.40M-6.37M-15.42M18.02M
Net Income Margin-53.42%-75.72%-49.43%-259.24%-117.44%-73.98%-50.67%-56.74%-70.27%-324.76%234.27%
Interest Expense0002.99M665.40K713.60K1.51M2.51M1.38M7.92M543.31K
Interest Expense % of Total Revenue0.00%0.00%0.00%64.10%10.83%8.78%12.98%22.24%15.26%166.88%7.06%

Balance Sheet

Currency: EUR2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.18M4.92M9.33M5.26M19.50M23.50M21.34M22.29M12.36M8.18M5.95M
Total Liabilities7.21M7.57M14.36M21.53M8.64M18.14M21.15M26.44M24.96M34.34M13.00M
Total Equity-1.03M-2.65M-5.03M-16.27M10.87M5.36M191.40K-4.16M-12.60M-26.16M-7.05M
Cash3.61M2.01M6.03M1.72M12.02M9.21M5.80M8.18M2.56M1.71M951.78K
Net Debt--4.70M8.81M-3.58M9.94M14.45M17.83M26.52M10.45M

Cash Flow

Currency: EUR2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-880.04K-2.53M-2.18M-4.32M-7.64M-6.88M-4.87M-5.20M-3.70M-2.40M-1.10M
Investing Cash Flow237.39K-112.53K-153.87K-228.90K-2.38M-3.96M-918.80K----
Financing Cash Flow2.82M1.04M6.36M229.70K20.32M8.01M2.38M----
Capital Expenditure81.94K112.53K153.92K229.10K2.34M3.96M918.80K227.60K128.50K00
Free Cash Flow---2.34M-4.54M-9.98M-10.85M-5.79M-5.43M-3.70M-2.40M-1.10M
FCF to OCF--107.05%105.31%130.64%157.57%118.88%104.37%100.00%100.00%100.00%

Earnings

Report DateMay 1, 2019Aug 30, 2019Nov 29, 2019Feb 26, 2020Apr 16, 2020Aug 27, 2020Nov 26, 2020Mar 3, 2021Apr 14, 2021Aug 25, 2021Nov 22, 2021Mar 2, 2022Apr 13, 2022Jul 21, 2022Nov 21, 2022Apr 19, 2023
EPS Estimate-----1.05-----------
EPS Actual-2.20-1.13-0.85-0.72-0.45-1.12-1.06-0.83-1.42-1.55-1.300.28-1.23-1.37-1.29-0.40
Surprise----57.14%-----------
TimingPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap8.00M
Enterprise Value18.45M
Trailing P/E0.41
Forward P/E4.03
Price / Sales1.00
Price / Book597.26
EPS9.76
Book Value-3.83
Revenue (TTM)7.96M
Gross Profit (TTM)6.54M
EBITDA48.02K
Profit Margin226.36%
Operating Margin-427.74%
Return on Equity-395.29%
Return on Assets-2.33%
Shares Outstanding2.00M
Shares Float1.37M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%